NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced that the Company will be presenting at the Morgan Stanley Global Consumer & Retail Conference…
Category: News
Eye Washing Can Help Manage Hay Fever Symptoms
Eye washing is linked to less severe ocular symptoms of hay fever, fewer flares, and more days without symptoms, according to a digital prospective study. Medscape Medical News
BTIG to Host 5th Annual Ophthalmology Day on December 1, 2025
NEW YORK–(BUSINESS WIRE)–BTIG announced today that its 5th Annual Ophthalmology Day will take place on Monday, December 1, 2025. The virtual, one-day event will include thematic panel discussions and one-on-one meetings. The event will be hosted by: …
AGCバイオロジクス、遺伝性網膜疾患向けにAAVantgardeのデュアルベクター遺伝子治療薬を製造へ
ミラン–(BUSINESS WIRE)–（ビジネスワイヤ） — AGCバイオロジクスは、AAVantgardeによるシリーズB資金調達ラウンドの完了直後も、同バイオテクノロジー企業との新たな製造契約を発表しました。これは、アデノ随伴ウイルス市場におけるAGCバイオロジクスの最新の進展となります。本契約の下、同社は、現在承認された治療法が存在せず、進行性かつ不可逆的な視力低下に対応するために設計されたAAVantgardeの2つの新規候補品について、Good Manufacturing Prac…
AGC Biologics produziert die Dual-Vektor-Gentherapien von AAVantgarde für erbliche Netzhauterkrankungen
MAILAND–(BUSINESS WIRE)–Nach dem Abschluss einer Serie-B-Finanzierungsrunde durch AAVantgarde hat AGC Biologics eine neue Produktionsvereinbarung mit dem Biotechnologieunternehmen bekannt gegeben. Damit hat AGC Biologics einen weiteren Meilenstein au…
AGC Biologics produrrà terapie geniche a doppio vettore di AAVantgarde mirate alle retinopatie ereditarie
MILANO–(BUSINESS WIRE)–Dopo la chiusura di un round di finanziamento di serie B da parte di AAVantgarde, AGC Biologics ha annunciato un nuovo accordo di produzione con l’azienda biotech, che rappresenta il progresso più recente di AGC Biologics nel m…
AGC Biologics to Manufacture AAVantgarde’s Dual-Vector Gene Therapies for Inherited Retinal Disorders
MILAN–(BUSINESS WIRE)– #Biotech–On the heels of AAVantgarde closing a Series B financing round, AGC Biologics announced a new manufacturing agreement with the biotechnology company, marking AGC Biologics’ latest advancement in the adeno-associated v…
U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
WHIPPANY, N.J.–(BUSINESS WIRE)–U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous NSCLC
Which Diagnostic Steps Help Spot Sjögren Syndrome Early?
Early recognition of Sjögren syndrome is essential because timely diagnosis and coordinated follow-up reduce systemic complications, including the risk for lymphoma. Medscape News UK
Does Poor Vision Put US Kids at Risk for Food Insecurity?
Children with impaired vision are about 70% more likely to experience food insecurity than those without eye issues, an association that remains significant after accounting for socioeconomic factors. Medscape Medical News
National Vision Holdings, Inc. Details Transformation Strategy and Long-Term Financial Objectives Underpinning Bold Reinvention
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) will host an Investor Day at NASDAQ MarketSite in New York City today to detail its comprehensive transformation strategy and financial outl…
Drug Used for Enlarged Prostate Tied to High Glaucoma Risk
The use of alpha-blockers for benign prostatic hyperplasia is tied to an increased risk of developing acute angle-closure glaucoma, a study finds. Medscape Medical News
Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor Day
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will outline the next chapter of its evolution today during an investor day event …
Tocilizumab Offers Durable Response in Steroid-Resistant TED
More than half of patients with moderate-to-severe thyroid eye disease who do not improve with corticosteroids achieve disease control after 6 months of treatment with tocilizumab. Medscape Medical News
Alcon Delivers Solid Third-Quarter 2025 Results with Accelerated Growth in Equipment and Ocular Health; Unity VCS Momentum Builds
GENEVA–(BUSINESS WIRE)–Alcon Delivers Solid Third-Quarter 2025 Results with Accelerated Growth in Equipment and Ocular Health; Unity VCS Momentum Builds
Alcon Delivers Solid Third-Quarter 2025 Results with Accelerated Growth in Equipment and Ocular Health; Unity VCS Momentum Builds
GENEVA–(BUSINESS WIRE)–Alcon Delivers Solid Third-Quarter 2025 Results with Accelerated Growth in Equipment and Ocular Health; Unity VCS Momentum Builds
Unexplained Pediatric Mucositis: Could It Be RIME?
Early diagnosis of reactive infectious mucocutaneous eruption is important to minimize potential long-term disease complications. Medscape Medical News
AAO 2025: AI’s Role in the Future of Retinal Disorders
Dr Sunir Garg explores how AI is transforming retinal care, from individualized treatments to tracking disease progression and bridging gaps across specialties. Medscape
Indigenous Canadians Face Barriers to Adequate Eye Care
Vision care for Canada’s Indigenous population is marked by the absence of early disease detection, accessible services, and a national eye care strategy. Medscape News Canada
Deciphering Diabetic Dilemmas
The Curbsiders tackle complex diabetes cases to help you learn how to manage hypoglycemia among older adults, retinopathy among pregnant individuals, and steroid-induced hyperglycemia. The Curbsiders